Aw. Blackstock et al., Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer, J CL ONCOL, 17(7), 1999, pp. 2208-2212
Purpose: To determine the maximum-tolerated dose, dose-limiting toxicities,
and potential antitumor activity of twice-weekly gemcitabine and concurren
t radiation in patients with locally advanced pancreatic cancer,
Patients and Methods: Nineteen patients with histologically confirmed adeno
carcinoma of the pancreas were studied at the Wake Forest University Baptis
t Medical Center and the University of North Carolina at Chapel Hill, The i
nitial dose of gemcitabine was 20 mg/m(2) by 30-minute intravenous infusion
each Monday and Thursday for 5 weeks concurrent with 50.4 Gy of radiation
to the pancreas. Gemcitabine doses were escalated in 20-mg/m(2) increments
in successive cohorts of three to six additional patients until dose-limiti
ng toxicity was observed,
Results: The dose-limiting toxicities at 60 mg/m(2) given twice-weekly were
nausea/vomiting, neutropenia, and thrombocytopenia. Twice-weekly gemcitabi
ne at a 40-mg/m(2) dose was well tolerated, Of the eight patients eligible
for a minimum follow-up of 12 months, three remain alive, one of whom has n
o evidence of disease progression,
Conclusion: A dose of twice-weekly gemcitabine at 40 mg/m(2) produced mild
thrombocytopenia, neutropenia, nausea, and vomiting when delivered with con
current radiation to the upper abdomen in patients with advanced pancreatic
cancer. These data suggest this regimen is well tolerated and may possess
significant activity. There data and other observations have resulted in a
phase II Cancer and Leukemia Group B study to ascertain the efficacy of thi
s treatment regimen in patients with locally advanced pancreatic cancer. (C
) 1999 by American Society of Clinical Oncology.